[
    [
        {
            "time": "",
            "orginal_text": "浙商证券维持药明康德买入评级，药明康德事件点评：激励加码，协同加深，持续看好",
            "features": {
                "keywords": [
                    "药明康德",
                    "买入评级",
                    "激励加码",
                    "协同加深"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "浙商证券维持药明康德买入评级，药明康德事件点评：激励加码，协同加深，持续看好",
            "scores": {
                "News_content": "浙商证券维持药明康德买入评级，药明康德事件点评：激励加码，协同加深，持续看好",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "速递 | 开发创新实体瘤TCR-T细胞疗法，新锐完成1.1亿美元B轮融资",
            "features": {
                "keywords": [
                    "TCR-T细胞疗法",
                    "融资",
                    "新锐公司"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "速递 | 开发创新实体瘤TCR-T细胞疗法，新锐完成1.1亿美元B轮融资",
            "scores": {
                "News_content": "速递 | 开发创新实体瘤TCR-T细胞疗法，新锐完成1.1亿美元B轮融资",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "速递 | 10亿美元助力球形核酸治疗神经退行性疾病，益普生成达成合作",
            "features": {
                "keywords": [
                    "球形核酸",
                    "神经退行性疾病",
                    "合作",
                    "益普生"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "速递 | 10亿美元助力球形核酸治疗神经退行性疾病，益普生成达成合作",
            "scores": {
                "News_content": "速递 | 10亿美元助力球形核酸治疗神经退行性疾病，益普生成达成合作",
                "Correlation": 4,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "速递 | 推进雌激素受体降解剂等抗癌药在中国开发，新锐获7500万美元助力",
            "features": {
                "keywords": [
                    "抗癌药",
                    "雌激素受体降解剂",
                    "融资"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "速递 | 推进雌激素受体降解剂等抗癌药在中国开发，新锐获7500万美元助力",
            "scores": {
                "News_content": "速递 | 推进雌激素受体降解剂等抗癌药在中国开发，新锐获7500万美元助力",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "药石科技靠投资跳进CDMO，硬扛药明剑指前三，不过目标成色存疑，也连亏五年了 投资失误",
            "features": {
                "keywords": [
                    "药石科技",
                    "CDMO",
                    "亏损",
                    "投资失误"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "药石科技靠投资跳进CDMO，硬扛药明剑指前三，不过目标成色存疑，也连亏五年了 投资失误",
            "scores": {
                "News_content": "药石科技靠投资跳进CDMO，硬扛药明剑指前三，不过目标成色存疑，也连亏五年了 投资失误",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "北上资金不惧调整逆势增仓，三季度重拾传统“大白马”",
            "features": {
                "keywords": [
                    "北上资金",
                    "增仓",
                    "大白马"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "投资"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "北上资金不惧调整逆势增仓，三季度重拾传统“大白马”",
            "scores": {
                "News_content": "北上资金不惧调整逆势增仓，三季度重拾传统“大白马”",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "百诚医药：逆天净利神话恐破灭 客户羸弱交易真实性存疑",
            "features": {
                "keywords": [
                    "百诚医药",
                    "净利下降",
                    "客户问题",
                    "交易真实性"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "百诚医药：逆天净利神话恐破灭 客户羸弱交易真实性存疑",
            "scores": {
                "News_content": "百诚医药：逆天净利神话恐破灭 客户羸弱交易真实性存疑",
                "Correlation": 4,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "恒生科技指数跌2.36%，热门科技股走低",
            "features": {
                "keywords": [
                    "恒生科技指数",
                    "下跌",
                    "科技股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "恒生科技指数跌2.36%，热门科技股走低",
            "scores": {
                "News_content": "恒生科技指数跌2.36%，热门科技股走低",
                "Correlation": 2,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 1,
                "Market_Scope": 10,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "港股异动 | CRO概念股集体走高 金斯瑞生物科技(01548)涨超9% 药明康德(02359)涨超5%",
            "features": {
                "keywords": [
                    "CRO概念股",
                    "金斯瑞生物科技",
                    "药明康德",
                    "上涨"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "港股异动 | CRO概念股集体走高 金斯瑞生物科技(01548)涨超9% 药明康德(02359)涨超5%",
            "scores": {
                "News_content": "港股异动 | CRO概念股集体走高 金斯瑞生物科技(01548)涨超9% 药明康德(02359)涨超5%",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "【恒指小幅高开】香港恒生指数开盘涨0.2%，报26289.06点。腾讯开盘跌超1%。奈雪的茶跌超8%，此前奈雪的茶曝出食品安全丑闻。阿里巴巴、美团小幅上涨。比亚迪股份延续涨势，高开逾5%。药明康德涨近7%，建议采纳2021年H股奖励信托计划。",
            "features": {
                "keywords": [
                    "恒生指数",
                    "高开",
                    "药明康德",
                    "H股奖励信托计划"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【恒指小幅高开】香港恒生指数开盘涨0.2%，报26289.06点。腾讯开盘跌超1%。奈雪的茶跌超8%，此前奈雪的茶曝出食品安全丑闻。阿里巴巴、美团小幅上涨。比亚迪股份延续涨势，高开逾5%。药明康德涨近7%，建议采纳2021年H股奖励信托计划。",
            "scores": {
                "News_content": "【恒指小幅高开】香港恒生指数开盘涨0.2%，报26289.06点。腾讯开盘跌超1%。奈雪的茶跌超8%，此前奈雪的茶曝出食品安全丑闻。阿里巴巴、美团小幅上涨。比亚迪股份延续涨势，高开逾5%。药明康德涨近7%，建议采纳2021年H股奖励信托计划。",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "orginal_text": "药明康德：董事会会议建议采纳2021年H股奖励信托计划及2021年股东权益一致性奖励计划",
            "features": {
                "keywords": [
                    "药明康德",
                    "H股奖励信托计划",
                    "股东权益"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "药明康德：董事会会议建议采纳2021年H股奖励信托计划及2021年股东权益一致性奖励计划",
            "scores": {
                "News_content": "药明康德：董事会会议建议采纳2021年H股奖励信托计划及2021年股东权益一致性奖励计划",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "药明康德(02359)建议采纳2021年H股奖励信托计划及75亿港元SAI奖励计划",
            "features": {
                "keywords": [
                    "药明康德",
                    "H股奖励信托计划",
                    "SAI奖励计划"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "药明康德(02359)建议采纳2021年H股奖励信托计划及75亿港元SAI奖励计划",
            "scores": {
                "News_content": "药明康德(02359)建议采纳2021年H股奖励信托计划及75亿港元SAI奖励计划",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        }
    ]
]